Analyst Insights

NPS Pharmaceuticals Shares Remain Undervalued, Says Janney Capital

In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair …

Cantor Fitzgerald Reiterates Hold On Jazz Pharmaceuticals Following 2Q14 Results

In a research note released yesterday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Jazz Pharmaceuticals (JAZZ) with a $151 price …

Roth Capital Sees Little Near-Term Price Upside For Keurig Shares

In a research report released yesterday, Roth Capital analyst Anton Brenner maintained a Neutral rating on Keurig Green Mountain (GMCR) with a $120 …

Roth Capital Maintains Buy On EnteroMedics Following 2Q14 Results

In a research report published yesterday, Roth Capital analyst Chris Lewis maintained a Buy rating on EnteroMedics Inc. (ETRM) with a $5 price …

Depomed: We Remain Neutral On The Name But With A Positive Bias, Says Roth Capital

Yesterday, Roth Capital analyst Scott Henry issued a note in which he reiterated a Neutral rating on Depomed Inc. (DEPO) with a $13.

Roth Capital Reiterates Buy On Celldex Following 2Q14 Results, Keeps $40 PT

In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (CLDX) with a $40 price …

Atmel: We Recommend Investors Remain On The Sidelines, Says Feltl

In a research note published yesterday, Feltl and Company analyst Jeffrey Schreiner reiterated a Hold rating on Atmel Corp. (ATML) with a $7.

Analyst Vs. Analyst: Nu Skin Enterprises – Who Do You Side With?

Nu Skin Enterprises (NUS) posted a big earnings miss on Wednesday, and analysts are taking a wait and see approach, while others are charging ahead. …

BioCryst Pharmaceuticals Quarterly Update; Roth Capital Reiterates Buy

In a research note issued August 6, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (BCRX) with a $20 …

H.C. Wainwright Reiterates Buy On BioCryst Pharmaceuticals, Sees 84% Upside

In a research report released yesterday, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts